Advancing the National Immunization Program in an era of achieving universal vaccine coverage in China and beyond

• Published in: Infectious diseases of poverty 2024-03, Vol.13 (1), p.25-5, Article 25
• Main Authors: Chen, Shu, Rodewald, Lance E, Du, Anna Heng, Tang, Shenglan
• Format: Article
• Language: English
• Subjects: Advocacy; Caregivers; Case studies; Cervical cancer; Child; China; Cities; COVID-19 Vaccines; Economic incentives; Families & family life; Global health; Health system strengthening; Human papillomavirus; Humans; Immunization; Immunization Programs; Infectious diseases; Innovations; Low income groups; Medical research; Medically uninsured persons; Medicine, Experimental; National Immunization Program; New vaccine introduction; Pediatrics; Pilot projects; Public awareness; Public health; R&D; Research & development; Rotavirus; Streptococcus infections; Universal vaccine coverage; Vaccination; Vaccines; Viruses
• ISSN: 2049-9957; 2095-5162; 2049-9957
• DOI: 10.1186/s40249-024-01192-6

Immunization is a cornerstone of public health. Despite great success, China's National Immunization Program (NIP) faces challenges, such as the integration of several World Health Organization-recommended vaccines and other systemic issues. The Innovation Laboratory for Vaccine Delivery Research (VaxLab), supported by the Bill & Melinda Gates Foundation and established in 2021 at Duke Kunshan University, focuses on enhancing China's NIP through research and policy advocacy. This editorial aims to summarize the key findings of the manuscripts published in the collection contributed by VaxLab team and set the future research agenda. The collection contains eleven manuscripts discussing China's immunization landscape and strategies to improve coverage, particularly for non-NIP vaccines like human papillomavirus vaccine (HPV), pneumococcal conjugate vaccine (PCV), Haemophilus influenzae type b vaccine (Hib), and rotavirus vaccines. Key findings include: (i) The COVID-19 vaccination campaign demonstrated China's capacity for rapid, large-scale immunization efforts, suggesting potential for broader vaccine coverage improvements; (ii) Efforts in combating cervical cancer through the HPV vaccine indicate progress but also highlight challenges like vaccine supply and equitable access; (iii) The lag in adopting higher-valent paediatric combination vaccines in China needs attention to address regulatory and health system hurdles; (iv) Disparities in access to non-NIP vaccines underscore the need for government initiatives to improve vaccine coverage, especially for remote areas and marginalized populations; (v) Original studies emphasize the influence of caregivers' knowledge, health workers' financial incentives, and concerns about vaccine efficacy on immunization rates; (vi) Case studies from the Weifang City of China and Indonesia to introduce PCV offer insights on successful vaccine introduction strategies and the impact of innovative financing and government support. The articles emphasize the need for government leadership, strategic policymaking, and public awareness to enhance vaccine coverage and equity. The VaxLab will continue strengthening China's NIP by focusing on vaccine financing, emphasizing diversity, equity, and inclusion, and improving maternal vaccination coverage. Research will extend to Southeast Asian and Western Pacific regions, especially in middle-income countries facing challenges in vaccine financing and delivery. The collective efforts